Gynecologic Oncology
Gynecologic Oncology
3 years ago

Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer

The objective of this study was to determine the overall tolerability and toxicity of olaparib capsules among older (≥65years) patients with recurrent ovarian cancer treated on 8 completed prospective trials of olaparib. Methods An ancillary data analysis of 398 patients with recurrent ovarian cancer enrolled on eight prospective trials of olaparib capsules was performed. Patients aged 65years and older were stratified into age groups by 5year increments (ages 65–69, 70–74, ≥75years) and compared to those <65. Analysis was restricted to those patients receiving the recommended treatment dose of 400mg PO b.i.d. Results Of the 398 patients included, 78 were ≥65 (age 65–69 n =38, age 70–74 n =23, age≥75 n =17). The majority of elderly patients were Caucasian (n=2 Asian) and had received ≥5 prior lines of chemotherapy. In patients <65, 46.9% required dose reduction as compared to 44.7% of patients 65–69years, 47.8% of patients 70–74years, and 64.7% of patients ≥75years (p =0.62). In patients <65years 41.2% required dose interruption, as compared to 50%, 43.5%, and 64.7% of patients aged 65–69, 70–74, and ≥75, respectively (p =0.11). There were no occurrences of myelodysplastic syndrome or acute myeloid leukemia in any of the older cohorts. Toxicities, including grade 3/4 nausea, were similar across age groups. Conclusions Tolerability and toxicity of olaparib capsules is similar between women ≥65years and <65years of age treated for advanced recurrent ovarian cancer. Use of olaparib should be considered in this patient population.

Publisher URL: www.sciencedirect.com/science

DOI: S0090825817313641

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.